Gallium-67 scintigraphy in lymphoma with bone involvement

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• Bone involvement is a common complication of both Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL).
• Traditional 99mTc-MDP bone scintigraphy is used for initial detection but is less effective for monitoring treatment response.
• 67Ga scintigraphy has emerged as a potential tool for assessing treatment efficacy in lymphoma.

Purpose of the Study:

• To evaluate the utility of Gallium-67 (67Ga) scintigraphy and SPECT in monitoring bone involvement and treatment response in lymphoma patients.
• To compare the diagnostic accuracy of 67Ga scintigraphy with 99mTc-MDP bone scintigraphy for detecting bone lesions in lymphoma.

Main Methods:

• Investigated Gallium-67 (67Ga) and 99mTc-MDP uptake in 20 patients with bone-involved lymphoma before treatment.
• Performed 67Ga scans in 16 patients for monitoring treatment response in bone lesions.
• Utilized SPECT imaging in conjunction with 67Ga scintigraphy.

Main Results:

• 67Ga scintigraphy diagnosed bone lesions in 19 out of 20 patients, while 99mTc-MDP detected lesions in all patients.
• 67Ga was also effective in detecting soft-tissue lymphoma lesions in 18 of 19 patients.
• 67Ga scintigraphy accurately monitored bone response to treatment in 15 out of 16 patients.

Conclusions:

• Gallium-67 (67Ga) uptake in lymphoma-involved bone is a reliable indicator for monitoring osseous response to treatment.
• 67Ga scintigraphy offers valuable insights into both bone and soft-tissue involvement in lymphoma.
• This imaging modality shows significant potential for managing lymphoma patients with bone disease.